Table 3. Serologic evaluation before and after RL.
| Serology | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Pre RL | ||||
| MELD score | 6 | 6 | 6 | 9 |
| ALBI grade | A1 | A1 | A1 | A2 |
| Albumin (g/dL) | 3.9 | 4.0 | 4.0 | 3.7 |
| Total Bilirubin (mg/dL) | 0.2 | 0.1 | 0.3 | 0.4 |
| Creatinine (mg/dL) | 0.61 | 0.8 | 0.83 | 0.84 |
| Sodium (mmol/L) | 140 | 141 | 136 | 136 |
| INR | 1 | 1 | 1 | 1.3 |
| Platelets (thou/cu-mm) | 226 | 275 | 121 | 216 |
| CEA (ng/mL) | 12.1 | 0.2 | 11.7 | 172 |
| 1 month post RL | ||||
| MELD | 6 | 6 | 6 | N/A* |
| Total Bilirubin (mg/dL) | 0.2 | 0.2 | 0.4 | 0.1 |
| Creatinine (mg/dL) | 0.55 | 0.8 | 0.77 | 0.74 |
| Sodium (mmol/L) | 138 | 140 | 135 | 139 |
| INR | 1.2 | 1 | 1 | N/A |
| Platelets (thou/cu-mm) | 224 | 204 | 108 | 194 |
| CEA (ng/mL) | 3.4 | 1.2 | 10.6 | 142 |
| 3 month post RL | ||||
| MELD | 6 | 7 | 9 | 7 |
| Total bilirubin (mg/dL) | 0.4 | 0.3 | 0.6 | 0.7 |
| Creatinine (mg/dL) | 0.52 | 0.86 | 0.85 | 0.9 |
| Sodium (mmol/L) | 140 | 139 | 133 | 135 |
| INR | 1 | 1.1 | 1.3 | 1.1 |
| Platelets (thou/cu-mm) | 222 | 206 | 98 | 170 |
| CEA (ng/mL) | 1.8 | 1.2 | 3.1 | 24 |
MELD, model for end stage liver disease; ALBI, albumin-bilirubin; CEA, carcinoembryonic antigen; INR, international normalized ratio.